Full Text View
Tabular View
No Study Results Posted
Related Studies
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
This study has been withdrawn prior to recruitment.
Study NCT00030355   Information provided by National Cancer Institute (NCI)
First Received: February 14, 2002   Last Updated: November 7, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Leukemia, Promyelocytic, Acute
More general conditions related to this trial
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
homoharringtonine
chemotherapy
Additional drug interventions recognized in this trial
Harringtonines
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
ChemGenex Therapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services